Immutrin

Immutrin is a biotechnology company dedicated to developing next-generation antibody therapies to deplete systemic amyloid deposits and reverse amyloidosis. The company's lead asset is being developed for the treatment of ATTR cardiomyopathy, a severe and progressive form of amyloidosis. Immutrin's antibody is a potential top-tier therapy with a unique mechanism of action designed to selectively and exclusively remove established amyloid fibrils.